Cargando…

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

INTRODUCTION: Emicizumab prophylaxis significantly reduces bleeding events; however, the associated impact on bone/joint health is unknown. AIM: To explore the effect of emicizumab prophylaxis on bone/joint health in people with haemophilia A (PwHA) without FVIII inhibitors enrolled in HAVEN 3 (NCT0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiialainen, Anna, Niggli, Markus, Kempton, Christine L., Castaman, Giancarlo, Chang, Tiffany, Paz‐Priel, Ido, Adamkewicz, Joanne I., Levy, Gallia G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796488/ https://www.ncbi.nlm.nih.gov/pubmed/35905294 http://dx.doi.org/10.1111/hae.14642

Ejemplares similares

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays
por: Adamkewicz, Joanne I., et al.
Publicado: (2019)

Low immunogenicity of emicizumab in persons with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
por: Kempton, Christine, et al.
Publicado: (2021)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial
por: Takeyama, Masahiro, et al.
Publicado: (2023)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence
por: Linari, Silvia, et al.
Publicado: (2020)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
por: Al-Banaa, Kadhim, et al.
Publicado: (2021)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study
por: Shima, Midori, et al.
Publicado: (2022)

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab
por: Valls, Raquel, et al.
Publicado: (2023)

A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A
por: Yoneyama, Koichiro, et al.
Publicado: (2021)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

A phase IV, multicentre, open‐label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures
por: Escobar, Miguel, et al.
Publicado: (2022)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US
por: Lewandowska, Magdalena, et al.
Publicado: (2020)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

A Comparison of the Incidence Rate for Joint Bleeding and FVIII Consumption between On-Demand versus Prophylaxis Factor VIII Replacement Therapy and the Direct Cost of Prophylaxis Treatment in Severe Haemophilia A Patients
por: Jamal, Munirah, et al.
Publicado: (2023)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors
por: Matsushita, Tadashi, et al.
Publicado: (2022)

Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021)

Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2016)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k0kc2csolqv7ap7nm1kvhpg4lh